NLRP3 and COVID-19: Similarly, we assessed the available literature in PubMed and Cochrane databases and in ClinicalTrials.gov (accessed on 3 December 2020) using the terms “NLRP3, COVID-19, probiotics” “SARS-CoV-2”, and their combination on the use of probiotics as immunomodulators of COVID-19 infection management through NLRP3 inflammasome manipulation.